Whitehawk Therapeutics (NASDAQ:WHWK) Stock Price Down 15.3% - Here's Why

Key Points

• Whitehawk Therapeutics stock dropped 15.3% to a last trading price of $2.21, with nearly 2.72 million shares traded during the decline.
• Analysts have mixed ratings on WHWK, with Zacks upgrading it to a hold but Weiss Ratings maintaining a sell rating, leading to an average rating of "Reduce".
• The company reported a significant earnings miss, with an EPS of ($0.76), falling short of the expected $0.49, and has a market cap of $104.15 million.

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) shares were down 15.3% during mid-day trading on Friday . The stock traded as low as $2.08 and last traded at $2.21. Approximately 2,719,309 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 4,825,615 shares. The stock had previously closed at $2.61.

Analyst Ratings Changes

Several equities research analysts recently issued reports on WHWK shares. Zacks Research raised shares of Whitehawk Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, October 7th. Weiss Ratings reissued a "sell (e+)" rating on shares of Whitehawk Therapeutics in a research report on Wednesday, October 8th. Finally, Wall Street Zen cut shares of Whitehawk Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Whitehawk Therapeutics currently has an average rating of "Reduce".

Whitehawk Therapeutics Trading Down 15.3%

The stock's fifty day moving average is $1.89. The firm has a market cap of $104.15 million, a PE ratio of -36.83 and a beta of 0.58.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of $0.49 by ($1.25). Whitehawk Therapeutics had a net margin of 99.42% and a negative return on equity of 75.99%.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.